Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Posttreatment effects of topiramate treatment for heavy drinking.

Alcoholism, clinical and experimental research - 1 Dec 2014

Kranzler Henry R, Wetherill Reagan, Feinn Richard, Pond Timothy, Gelernter Joel, Covault Jonathan

Abstract excerpt

BACKGROUND: We examined whether the effects of topiramate and a single nucleotide polymorphism (rs2832407) in GRIK1, which encodes a kainate receptor subunit, persisted following a 12-week, placebo-controlled trial in 138 heavy drinkers with a treatment goal of reduced drinking. During treatment, topiramate 200 mg/d significantly reduced heavy drinking days and increased the frequency of abstinent days (Am J...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Drinking

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alcoholic Intoxication

Share to Follow-Up Studies

Share to Polymorphism, Single Nucleotide

Share to Receptors, Kainic Acid

Share to Time Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25581656
DOI: 10.1111/acer.12578
PMCID: PMC4293099

Genes

GRIK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Posttreatment effects of topiramate treatment for heavy drinking.PMID 25581656Read ↗

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Semantic proximity Read ↗

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.Semantic proximity Read ↗

Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.Semantic proximity Read ↗

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Semantic proximity Read ↗

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.Semantic proximity Read ↗

GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.Semantic proximity Read ↗

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Semantic proximity Read ↗

Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.Semantic proximity Read ↗

Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate.Semantic proximity Read ↗

Molecular correlates of topiramate and <i>GRIK1</i> rs2832407 genotype in pluripotent stem cell-derived neural culturesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.